CoChat

The novel BET‐CBP/p300 dual inhibitor NEO2734 is active in SPOP mutant and wild‐type prostate cancer

Open access
Yan, Yuqian, Ma, Jian, Wang, Dejie, Lin, Dong, Pang, Xiaodong, Wang, Shangqian, Zhao, Yu, Shi, Lei, Xue, Hui, Pan, Yunqian, Zhang, Jun, Wahlestedt, Claes, Giles, Francis J, Chen, Yu, Gleave, Martin E, Collins, Collin C, Ye, Dingwei, Wang, Yuzhuo, Huang, Haojie · 2019 · EMBO Molecular Medicine
Cited by 92

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

Abstract

CULLIN3-based E3 ubiquitin ligase substrate-binding adaptor gene SPOP is frequently mutated in prostate cancer (PCa). PCa harboring SPOP hotspot mutants (e.g., F133V) are resistant to BET inhibitors because of aberrant elevation of BET proteins. Here, we identified a previously unrecognized mutation Q165P at the edge of SPOP MATH domain in primary and metastatic PCa of a patient. The Q165P mutation causes structural changes in the MATH domain and impairs SPOP dimerization and substrate degradation. Different from F133V hotspot mutant tumors, Q165P mutant patient-derived xenografts (PDXs) and organoids were modestly sensitive to the BET inhibitor JQ1. Accordingly, protein levels of AR, BRD4 and downstream effectors such as RAC1 and phosphorylated AKT were not robustly elevated in Q165P mutant cells as in F133V mutant cells. However, NEO2734, a novel dual inhibitor of BET and CBP/p300, is active in both hotspot mutant (F133V) and non-hotspot mutant (Q165P) PCa cells in vitro and in vivo. These data provide a strong rationale to clinically investigate the anti-cancer efficacy of NEO2734 in SPOP-mutated PCa patients.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.15252/emmm.201910659

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 8 references

Cited by

See all 92

Metadata

Authors
Yan, Y., Ma, J., Wang, D., Lin, D., Pang, X., Wang, S., Zhao, Y., Shi, L., Xue, H., Pan, Y., Zhang, J., Wahlestedt, C., Giles, F. J., Chen, Y., Gleave, M. E., Collins, C. C., Ye, D., Wang, Y., & Huang, H.
Venue
EMBO Molecular Medicine
Published
2019-09-26
Volume
11
Issue
11
Pages
e10659-e10659
ISSN
  • 1757-4676 (ISSN-L)
  • 1757-4684
OpenAlex
W2976879024
Cited by
92
References
8
FWCI
3.15
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The novel BET‐CBP/p300 dual inhibitor NEO2734 is active in SPOP mutant and wild‐type prostate cancer. https://app.cochat.ai/papers/10.15252/emmm.201910659
The paper
Yan, Y., Ma, J., Wang, D., Lin, D., Pang, X., Wang, S., Zhao, Y., Shi, L., Xue, H., Pan, Y., Zhang, J., Wahlestedt, C., Giles, F. J., Chen, Y., Gleave, M. E., Collins, C. C., Ye, D., Wang, Y., & Huang, H. (2019). The novel BET‐CBP/p300 dual inhibitor NEO2734 is active in SPOP mutant and wild‐type prostate cancer. EMBO Molecular Medicine. https://doi.org/10.15252/emmm.201910659

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.